This study explored the treatment pattern of newly diagnosed type 2 diabetes (T2D) patients in 2015 using the Commercial and Medicare MarketScan databases. Therapy lines were defined in Table 1. A total of 115,091 adult patients with newly diagnosed (Dx) T2D were identified. Of patients who had antidiabetic drug (ADD) claims within a year after first T2D Dx (n = 53,041), about 20% progressed to second line. The average time from initial Dx to first line and from first to second line were 53 and 117 days respectively. The proportion of combination therapy (≥ 2 ADDs) was increased from 12% in first line to 63% in second line. Table 1 captured the top 20 therapies in each line. About 76% of patients started with metformin (MET) as monotherapy or in combination with sulfonylurea (SU). Substantial variation exists in second line therapies with SU leading the top monotherapy (8.7%). A very small number of patients received newer drugs such as dapagliflozin, dulaglutide and empagliflozin. In line with ADA recommendations, the majority of patients initiated MET-based regimens in first line. SUs were widely used in second line. Despite ongoing research and drug development, little has changed in prescribing of ADD, suggesting a need for better understanding of the gaps in diabetes management and/or education on use and benefits of newer drugs. This study most likely underestimated ADD therapy due to lack of prescriptions filled without pharmacy benefits.


J. Wu: None. J. Xie: None. S. Wong-Jacobosn: None. V.S. Haynes: Employee; Self; Eli Lilly and Company. Stock/Shareholder; Self; Eli Lilly and Company. Z. Zhao: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at